ストックスクリーナーアプリを入手
44.08
7.41%
-3.53
アフターアワーズ：
44.58
0.50
+1.13%
前日終値:
$47.61
開ける：
$48.41
24時間の取引高:
915.38K
Relative Volume:
0.71
時価総額：
$4.52B
収益：
$1.54M
当期純損益:
$-423.10M
株価収益率:
-9.7221
EPS:
-4.534
ネットキャッシュフロー:
$-356.03M
1週間 パフォーマンス:
-1.59%
1か月 パフォーマンス:
-20.36%
6か月 パフォーマンス:
+54.78%
1年 パフォーマンス:
+25.19%
1日の値動き範囲:
$44.02
$48.41
1週間の範囲:
$43.94
$48.58
52週間の値動き範囲:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
名前
Crinetics Pharmaceuticals Inc
セクター
電話
858-450-6464
住所
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
44.08 | 4.88B | 1.54M | -423.10M | -356.03M | -4.534 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-10 | 開始されました | Goldman | Neutral |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-11 | 開始されました | TD Cowen | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Peer Perform |
| 2025-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-01-16 | 開始されました | Morgan Stanley | Overweight |
| 2023-12-21 | 開始されました | Jefferies | Hold |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 開始されました | Oppenheimer | Outperform |
| 2023-04-24 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Robert W. Baird | Outperform |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-23 | 開始されました | Evercore ISI | Outperform |
| 2021-06-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 開始されました | ROTH Capital | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-13 | 開始されました | JP Morgan | Neutral |
| 2018-08-13 | 開始されました | Leerink Partners | Outperform |
| 2018-08-13 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (CRNX) Price Events - Stock Traders Daily
Recap Report: Is RSSS affected by consumer sentimentJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Weekly Recap: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Performance Report & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewswire
Recap Report: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Growth Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook On Its 70% Upside Potential - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK) - The Globe and Mail
Lisanti Capital Growth LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Momentum Shift: Can Crinetics Pharmaceuticals Inc. stock outperform in a bear marketWeekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities - Investing.com
Why (CRNX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: Is Crinetics Pharmaceuticals Inc exposed to currency risks2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists - Sahm
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - Sahm
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Crinetics Pharmaceuticals Inc (CRNX) 財務データ
収益
当期純利益
現金流量
EPS
Crinetics Pharmaceuticals Inc (CRNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kalofonos Isabel | Chief Commercial Officer |
Jan 05 '26 |
Option Exercise |
40.59 |
2,500 |
101,475 |
3,334 |
| Kalofonos Isabel | Chief Commercial Officer |
Jan 05 '26 |
Sale |
55.00 |
2,500 |
137,500 |
834 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):